Kenvue Inc. (NYSE:KVUE) Stake Reduced by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lowered its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 17.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,858 shares of the company's stock after selling 35,964 shares during the quarter. Rockefeller Capital Management L.P.'s holdings in Kenvue were worth $4,061,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Isthmus Partners LLC increased its holdings in Kenvue by 2.8% in the third quarter. Isthmus Partners LLC now owns 550,504 shares of the company's stock valued at $12,733,000 after buying an additional 14,964 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Kenvue by 30.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 9,992,933 shares of the company's stock worth $231,137,000 after acquiring an additional 2,316,443 shares in the last quarter. Public Sector Pension Investment Board increased its holdings in shares of Kenvue by 1,822.6% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,415,737 shares of the company's stock valued at $32,746,000 after acquiring an additional 1,342,100 shares during the last quarter. FORA Capital LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at approximately $6,014,000. Finally, RBO & Co. LLC lifted its stake in Kenvue by 40.7% during the third quarter. RBO & Co. LLC now owns 991,419 shares of the company's stock worth $22,932,000 after purchasing an additional 286,929 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Monday, September 23rd. Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price objective for the company. Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Finally, Royal Bank of Canada cut Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price target on the stock. in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $22.64.

Kenvue Stock Performance

Kenvue stock traded down $0.29 during mid-day trading on Friday, hitting $22.84. 9,708,660 shares of the company's stock traded hands, compared to its average volume of 17,762,063. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market cap of $43.79 billion, a PE ratio of 41.53, a price-to-earnings-growth ratio of 2.13 and a beta of 1.36. The firm has a 50 day moving average price of $22.97 and a 200 day moving average price of $21.09. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company's revenue was down .4% on a year-over-year basis. During the same period in the previous year, the business earned $0.31 earnings per share. On average, equities analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.59%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.